3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT.
Timothy J IvesonKathleen Anne BoydRachel S KerrJose Antonio Robles-ZuritaMark P SaundersAndrew H BriggsJim CassidyNiels Henrik HollanderJosep TaberneroAndrew HaydonBengt GlimeliusAndrea HarkinKaren AllanJohn McQueenSarah PearsonAshita WaterstonLouise MedleyCharles WilsonRichard EllisSharadah EssapenAmandeep S DhaddaMark HarrisonStephen FalkSherif RaoufCharlotte ReesRene K OlesenDavid J PropperJohn A BridgewaterAshraf AzzabiDavid FarrugiaAndrew WebbDavid CunninghamTamas HickishAndrew WeaverSimon GollinsHarpreet S WasanJames PaulPublished in: Health technology assessment (Winchester, England) (2020)
This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 23, No. 64. See the NIHR Journals Library website for further project information. This research was supported by the Medical Research Council (transferred to NIHR Evaluation, Trials and Studies Coordinating Centre - Efficacy and Mechanism Evaluation; grant reference G0601705), the Swedish Cancer Society and Cancer Research UK Core Clinical Trials Unit Funding (funding reference C6716/A9894).